180. Hull CM, Nickolay LE, Estorninho M, et al. Generation of human islet-specific regulatory T cells by TCR gene transfer. *J Autoimmun.* 2017;79:63-73.

181. Wright GP, Notley CA, Xue S-A, et al. Adoptive therapy with redi-rected primary regulatory T cells results in antigen-specific suppres-sion of arthritis. *Proc Natl Acad Sci USA.* 2009;106(45):19078-19083.

182. Rivière I, Sadelain M. Chimeric antigen receptors: a cell and gene therapy perspective. *Mol Ther.* 2017;25(5):1117-1124.

183. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci USA.* 1993;90(2):720-724.

184. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Invest.* 2011;121(5):1822-1826.

185. Zhao Z, Condomines M, van der Stegen S, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. *Cancer Cell.* 2015;28(4):415-428.

186. Van Schandevyl S, Kerre T. Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. *Acta Clin Belg.* 2018;13:1-7.

187. Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. *Curr Res Transl Med.* 2017;65(3):93-102.

188. Jain MD, Davila ML. Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies: principles of CAR T therapy. *Stem Cells.* 2018;36(1):36-44.

189. Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. *Gastroenterology.* 2008;134(7):2014-2024.

190. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. *Mol Ther.* 2014;22(5):1018-1028.

191. Trzonkowski P, Bieniaszewska M, Juścińska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4⁺CD25⁺CD127⁻ T regulatory cells. *Clin Immunol.* 2009;133(1):22-26.

192. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. *Blood.* 2011;117(14):3921-3928.

193. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. *Blood.* 2011;117(3):1061-1070.

194. Brunstein CG, Blazar BR, Miller JS, et al. Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. *Biol Blood Marrow Transplant.* 2013;19(8):1271-1273.

195. Boardman DA, Philippeos C, Fruhwirth GO, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. *Am J Transplant.* 2017;17(4):931-943.

196. Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. *Am J Transplant.* 2017;17(4):917-930.

197. Pierini A, Iliopoulou BP, Peiris H, et al. T cells expressing chimeric antigen receptor promote immune tolerance. *JCI Insight.* 2017;2(20):92865.

198. Okada M, Kanamori M, Someya K, Nakatsukasa H, Yoshimura A. Stabilization of Foxp3 expression by CRISPR-dCas9-based

epigenome editing in mouse primary T cells. *Epigenetics Chromatin.* 2017;10:24.

199. Konopacki C, Pritykin Y, Rubtsov Y, Leslie CS, Rudensky AY. Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function. *Nat Immunol.* 2019;20(2):232-242.

200. Miska J, Lee-Chang C, Rashidi A, et al. HIF-1α is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. *Cell Rep.* 2019;27(1):226-237.e4.

201. Xu Y, Melo-Cardenas J, Zhang Y, et al. The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine-induced ER stress response. *JCI Insight.* 2019;4(5):121887.

202. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk Gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. The San Raffaele Hospital, Milan, Italy. *Hum Gene Ther.* 1995;6(6):813-819.

203. Tiberghien P, Cahn J-Y, Brion A, et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Laboratoire d'Historiabilité et Thérapeutique Immuno-Moléculaire, Besançon, France. *Hum Gene Ther.* 1997;8(5):615-624.

204. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. *Mol Ther Oncolytics.* 2016;3:16011.

205. Tey S-K, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. *Biol Blood Marrow Transplant.* 2007;13(8):913-924.

206. Zhou X, Di Stasi A, Tey S-K, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. *Blood.* 2014;123(25):3895-3905.

207. Straathof KC. An inducible caspase 9 safety switch for T-cell therapy. *Blood.* 2005;105(11):4247-4254.

208. Minagawa K, Al-Obaidi M, Di Stasi A. Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for cancer immunotherapy. *Methods Mol Biol.* 2019;1895:57-73.

209. Wilkie S, van Schalkwyk M, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. *J Clin Immunol.* 2012;32(5):1059-1070.

210. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nat Biotechnol.* 2013;31(1):71-75.

211. Roybal K, Rupp L, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. *Cell.* 2016;164(4):770-779.

212. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. *Sci Transl Med.* 2013;5(215):215ra172.

213. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. *Nat Rev Immunol.* 2016;16(2):90-101.

**How to cite this article:** Flippe L, Bézie S, Anegon I, Guillonneau C. Future prospects for CD8⁺ regulatory T cells in immune tolerance. *Immunol Rev.* 2019;292:209-224. https://doi.org/10.1111/imr.12812